Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands

被引：0
|
作者：
Heisen, M.
Treur, M. J.
van der Hel, W. S.
Groot, M. T.
Verheggen, B. G.
机构：
[1] Pharmerit Europe, Rotterdam, Netherlands
[2] Novartis Pharma BV, Arnhem, Netherlands
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [11] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [12] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [13] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [14] Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
    Kalincik, T.
    Horakova, D.
    Spelman, T.
    Jokubaitis, V.
    Trojano, M.
    Lugaresi, A.
    Izquierdo, G.
    Rozsa, C.
    Grammond, P.
    Alroughani, R.
    Duquette, P.
    Girard, M.
    Pucci, E.
    Lechner-Scott, J.
    Slee, M.
    Fernandez-Bolanos, R.
    Grand'Maison, F.
    Hupperts, R.
    Verheul, F.
    Hodgkinson, S.
    Oreja-Guevara, C.
    Spitaleri, D.
    Barnett, M.
    Terzi, M.
    Bergamaschi, R.
    McCombe, P.
    Sanchez-Menoyo, J.
    Simo, M.
    Csepany, T.
    Rum, G.
    Boz, C.
    Havrdova, E.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 195 - 196
  • [15] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [16] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    JOURNAL OF NEUROLOGY, 2014, 261 : S303 - S303
  • [17] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 457 - 457
  • [18] Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lienert, C.
    Benkert, P.
    Beer, S.
    Hanni, P.
    Pardini, M.
    D'Souza, M.
    Derfuss, T.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    SWISS MEDICAL WEEKLY, 2016, 146 : 49S - 49S
  • [19] Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lienert, C.
    Benkert, P.
    Beer, S.
    Hanni, P.
    Pardini, M.
    D'Souza, M.
    Derfuss, T.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 627 - 627
  • [20] Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
    Kalincik, Tomas
    Brown, J. William L.
    Robertson, Neil
    Willis, Mark
    Scolding, Neil
    Rice, Claire M.
    Wilkins, Alastair
    Pearson, Owen
    Ziemssen, Tjalf
    Hutchinson, Michael
    McGuigan, Christopher
    Jokubaitis, Vilija
    Spelman, Tim
    Horakova, Dana
    Havrdova, Eva
    Trojano, Maria
    Izquierdo, Guillermo
    Lugaresi, Alessandra
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Grammond, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Sola, Patrizia
    Hupperts, Raymond
    Lechner-Scott, Jeannette
    Terzi, Murat
    Van Pesch, Vincent
    Rozsa, Csilla
    Grand'Maison, Francois
    Boz, Cavit
    Granella, Franco
    Slee, Mark
    Spitaleri, Daniele
    Olascoaga, Javier
    Bergamaschi, Roberto
    Verheul, Freek
    Vucic, Steve
    McCombe, Pamela
    Hodgkinson, Suzanne
    Sanchez-Menoyo, Jose Luis
    Ampapa, Radek
    Simo, Magdolna
    Csepany, Tunde
    Ramo, Cristina
    Cristiano, Edgardo
    Barnett, Michael
    Butzkueven, Helmut
    Coles, Alasdair
    LANCET NEUROLOGY, 2017, 16 (04): : 271 - 281
12345